Scancell Holdings PLC shares soared on Monday after the cancer immunotherapies developer said its phase 1/2 clinical trial with Modi-1 has opened for recruitment.

Shares shot up 29% to 13.89 pence each on Monday morning in London.

Modi-1 is a cancer vaccine for the treatment of solid tumours. The name of its clinical trial is ModiFY.

The Nottingham, England-based firm said oncology clinical research sites and investigators across the UK have agreed to contribute patients to the ModiFY study.

The first clinical sites are open for recruitment, and the company expects up to 20 sites to be open and recruiting ‘in due course.’

Scancell noted that the UK’s Medicines & Healthcare Products Regulatory Authority also approved a protocol amendment, that is aimed at accelerating patient recruitment and shortening study timelines.

Early safety and immunogenicity data is anticipated to be available in the second half of this year, and potential efficacy data is expected in 2023.

The study is a first-in-human clinical trial in patients with triple negative breast cancer, ovarian cancer, head and neck cancer, and renal cancer, Scancell said.

Modi-1 will be administered alone and in combination with checkpoint inhibitors in patients where the checkpoint inhibitors is standard of care.

Copyright 2022 Alliance News Limited. All Rights Reserved.